Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
- Monday, July 6, 2020, 7:15
- PR Newswire
- Add a comment
ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D)…
About the Author
admin has written 20655 stories on this site.